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Background. Advanced age is associated with a poorer prognosis in patients with melanoma. Despite this established ﬁnding, a
decreased incidence of positive sentinel lymph nodes (SLNs) with advancing age has paradoxically been described. Methods. Using
a single-institution database of melanoma patients between 1994 and 2009, the relationship between standard clinicopathologic
variables and recurrence based on age was evaluated. Results. 1244 patients who underwent successful SLN biopsies were analyzed
(mean followup 80.3 months). Increasing age was independently associated with worse survival on multivariable analysis (P =
0.02). SLN status was more likely to be negative if the patient was older (P = 0.01). Conclusions. Our data supports the paradox
that increasing age is associated with a lower frequency of positive-SLN biopsies despite age itself being a poor prognostic factor.
Weproposethatage-dependentvariationsintheprimarytumorandthepatientmaypredisposetoahematogenousrouteofspread
for the older population, leading to worse survival.
1.Introduction
One of the most signiﬁcant advances in the management of
melanoma has been the adoption of the sentinel lymph node
(SLN) technique. This procedure, through the cooperation
between surgery, nuclear medicine, and pathology, has en-
abled surgeons to identify patients with subclinical nodal
metastases. For those patients with a positive SLN, more ag-
gressive treatments like lymphadenectomies can be perform-
ed, and for those patients with a negative SLN, these poten-
tially morbid procedures may be safely avoided [1].
For patients with stages I and II melanoma, a positive SLN
is the single most important factor that determines over-
all prognosis and survival [1, 2]. Like SLN status, advanced
age is also associated with poorer prognosis in patients with
melanoma [1, 3, 4]. Furthermore, previous studies have de-
monstratedthatincreasingageiscorrelatedtootherpoorpro
gnostic features [5]. Paradoxically, in spite of these ﬁndings,
a decreased incidence of positive sentinel lymph nodes
(SLNs)withadvancingagehasbeendescribed[2,6].Possible
explanations for this observation include age-dependent var-
iations in metastatic spread, with older patients predisposed
to distant metastasis via a hematogenous route compared
with younger counterparts. We examined this hypothesis by
reviewingthe recurrencepatterns and other clinicopatholog-
ical variables as a function of age.
2. Methods
2.1. Patients and Methods. After obtaining appropriate
Emory University Institutional Review Board (IRB) approv-
al, we undertook a retrospective query of our institutional
melanoma database all patients undergoing SLN from 1994
to 2009, identifying 1244 patients with complete records.
Mean followup was 80.3 months. Pure desmoplastic cases
and those without complete data were excluded. Clinical and2 International Journal of Surgical Oncology
tumor variables examined included initial SLN status, gen-
der, ulceration, depth, primary tumor site, and age. Recur-
r e n c ep a t t e r n sw e r er e c o r d e da sl o c a l ,i ns i t u ,r e g i o n a l ,o r
distant.
2.2. SLN Mapping and Biopsy. SLN biopsy was performed as
described previously [1]. All patients underwent lymphosci-
ntigraphy preoperatively using ﬁltered technetium—99m—
sulfur colloid. Vital blue dye injected at the time of surgery
was used routinely in the latter half of the study. Measure-
ments of radioactivity in the radiolabeled lymph nodes were
made intraoperatively with a hand-held gamma probe. Peak
counts or counts accumulated over a 10-second count were
recorded. SLNs were removed until the lymphatic bed count
fell to 10 percent of the hottest SLN in the bed. Pathological
handling of the SLNs was as follows: (1) SLNs 3 to 4mm
in maximum dimension were entirely embedded, (2) larger
lymph nodes up to 1.0cm were bisected parallel to the long
axis and both halves entirely submitted cut face down in cas-
settes, and (3) SLNs larger than 1.0cm were transected into
three, four, or more pieces at 2-3mm intervals and all sec-
tions were embedded. One hematoxylin and eosin-stained
section and two immunostains (S100 and HMB-45) of each
SLNwerecutasserialsections1,2,3,and4,respectively,after
obtaining a full-face section.
2.3. Statistical Analysis. Age was categorized according to the
decade and as a continuous variable.
Both age categorization schemes were used in univariate
and multivariable models to examine primary tumor char-
acteristics, recurrence patterns, and survival. For univariate
analysis a Chi-Square was used for categorical variables and
an ANOVA test used for continuous variables. For multivari-
able analysis, a binomial logistic regression was used. Sur-
vivalandtimetorecurrencewereassessedwithKaplanMeier
curves and log rank computation. A P value of less than 0.05
on two-tailed analysis was used as the metric for statistical
signiﬁcance.
3. Results
Complete data was available on 1244 SLN biopsies, perform-
ed between 1994 and 2009. 1019 (81.9%) were SLN negative,
742 (59.6%) were male, 280 (22.5%) were ulcerated, the
mean Breslow depth was 2.45mm, and distribution by site
was 194 (15.6%) head and neck, 281 (22.6%) upper extrem-
ity, 501 (40.3%) trunk, and 267 (21.5%) lower extremity.
Each demographic variable stratiﬁed by decade is found in
Table 1.With80.3meanmonthsoffollowup,235patientsre-
curred: 104 distant, 50 regionally, 22 in transit (without re-
gional basin involvement), and 22 local; 37 recurrences were
combined sites.
Incorporatingthesamepreviouslydescribedclinicopath-
ologiccharacteristics,amultivariablemodelexaminingover-
all melanoma speciﬁc survival was used, using age as both a
continuous variable and as a categorical variable by decade,
demonstrating that age is associated with worse survival in
both paradigms (Tables 2(a) and 2 (b)). Using Kaplan Meier
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Figure 1: Increased age is associated with poorer survival (P =
0.01).
survival curves as a univariate representation of survival, we
further demonstrate that increased age (by decade) is asso-
ciated with worse prognosis (P = 0.01) (Figure 1). When
stratifying by decade on Kaplan Meier analysis, all decades
demonstrated that head and neck primary site was a poor
prognosticsign(≤30yrs,P = 0.02;31–40yrs,P = 0.001;41–
50yrs, P<0.001; 51–60yrs, P = 0.001; ≥61yrs, P = 0.002
(plots not shown)).
We compared both regional and distant recurrence pat-
terns stratiﬁed by age. SLN-negative patients (and not SLN-
positive patients) were analyzed aﬀording a sample size of
107 (8.6%). We found a nonstatistically supported trend of
increased distant recurrences by age after a negative-SLN
biopsy (P = 0.13) (Table 3). Using the same described multi-
variable model (with age categorized by decade), our data
demonstrate that increased age is associated with increased
risk of distant recurrence over regional recurrence (Table 4).
A similar trend is evident inversely, as increased age is asso-
ciated with a trend toward decreased SLN positivity on mul-
tivariable analysis (Table 5).
4. Discussion
As the application of SLN biopsy in melanoma becomes
more widespread, it is not surprising that there is a growing
body of theliterature ofretrospective studies examining clin-
icopathologicvariablesandrecurrencepatternsinmelanoma
after SLN biopsy [1, 5]. These retrospective studies, like ours,
are invaluable in that they help to characterize the questions
that we should ask and they tailor our thinking about the
biology of the disease. However, with this increasing bodyInternational Journal of Surgical Oncology 3
Table 1: Patient clinicopathologic variables, based on decade of life.
Variable All patients
≤30yrs 31–40yrs 41–50yrs 51–60yrs ≥61yrs
P values calculated for deciles n = 110 n = 173 n = 268 n = 299 n = 394
SLN
SLN− 1019 (81.9) 86 (78.2) 136 (78.6) 221 (82.5) 242 (80.9) 334 (84.8)
SLN+ 225 (18.1) 24 (21.8) 37 (21.4) 47 (17.5) 57 (19.1) 60 (15.2)
P = 0.32
Gender
Male 742 (59.6) 54 (49.1) 86 (49.7) 143 (53.4) 199 (66.6) 260 (66.0)
Female 502 (40.4) 56 (50.9) 87 (50.3) 125 (46.6) 100 (33.4) 134 (34.0)
P<0.001
Ulcer
Ulcerated 280 (22.5) 20 (18.2) 28 (16.2) 62 (23.1) 66 (22.1) 104 (26.4)
No ulcer 964 (77.5) 90 (81.8) 145 (83.8) 206 (79.6) 233 (77.9) 290 (73.6)
P = 0.01
Breslow depth (mm) (mean) 2.45 2.23 1.82 2.38 2.40 2.86
P<0.001
General site
Head & Neck 194 (15.6) 21 (19.1) 16 (19.2) 31 (11.6) 42 (14.0) 84 (21.4)
UE 281 (22.6) 21 (19.1) 32 (18.5) 63 (23.5) 72 (24.1) 93 (21.7)
Trunk 501 (40.3) 47 (19.1) 83 (48.0) 116 (43.3) 124 (41.5) 131 (33.3)
LE 267 (21.5) 21 (42.7) 42 (24.3) 58 (21.6) 61 (20.4) 86 (21.6)
P<0.01
Table 2: Multivariable analysis of overall survival, using age by continuous variable and by decade.
(a)
Variable Hazard ratio 95% conﬁdence interval P value
SLN POS 4.8 3.35–6.87 <0.001
Male 1.5 1.07–2.20 0.02
Age (continuous) 1.02 1.01–1.03 0.02
Breslow depth (≥1mm) 2.9 1.15–7.35 0.03
Ulceration 2.24 1.58–3.16 <0.001
Head and neck site 3.07 2.09–4.51 <0.001
(b)
Variable Hazard ratio 95% conﬁdence interval P value
SLN POS 4.78 3.34–6.86 <0.001
Male 1.51 1.05–2.17 0.02
Age
<30 versus 31–40yrs 1.56 0.70–3.56 0.28
<30 versus 41–50yrs 1.36 0.63–2.94 0.44
<30 versus 51–60yrs 2.07 0.99–4.33 0.05
<30 versus ≥61yrs 2.68 1.31–5.47 0.01
Breslow depth (≥1mm) 2.97 1.17–7.52 0.02
Ulceration 2.27 1.61–3.22 <0.001
Head and neck site 3.06 2.07–4.51 <0.0014 International Journal of Surgical Oncology
Table 3: Regional versus distant recurrence based on decade of age, (including only SLN NEG, n = 107).
Recurrence pattern ≤30yrs 31–40yrs 41–50yrs 51–60yrs ≥61yrs Total
P = 0.13 n = 110 n = 173 n = 268 n = 299 n = 394
Regional 1 (33.3) 7 (58.3) 7 (36.8) 6 (23.1) 13 (27.7) 34 (31.8)
Distant 2 (66.7) 5 (41.7) 12 (63.2) 20 (76.9) 34 (72.3) 73 (68.2)
Total 3 12 19 26 47 107
Table 4: Multivariable model of distant recurrence versus regional recurrences (only SLN negatives and distant/regional recurrences, n =
107).
Variable Hazard ratio 95% conﬁdence interval P value
Male 1.90 0.72–5.00 0.19
Age
<30 versus 31–40yrs 2.10 0.83–9.21 0.25
<30 versus 41–50yrs 3.00 0.68–13.3 0.15
<30 versus 51–60yrs 4.64 1.05–20.6 0.04
<30 versus ≥61yrs 2.78 0.70–11.0 0.15
Breslow depth (≥1mm) 1.90 0.72–5.00 0.19
Ulceration 1.96 0.74–5.24 0.18
Head and neck site 0.83 0.32–2.15 0.71
Table 5: Multivariate model for predicting SLN positivity with age based on quartiles demonstrates a trend that increasing age is associated
with decreased SLN positivity.
Variable Hazard ratio 95% conﬁdence interval P value
Male 1.76 1.28–2.42 0.001
Age
<30 versus 31–40yrs 1.01 0.56–1.85 0.96
<30 versus 41–50yrs 0.68 0.39–1.20 0.19
<30 versus 51–60yrs 0.75 0.43–1.31 0.31
<30 versus ≥61yrs 0.53 0.30–0.91 0.02
Breslow depth (≥1mm) 7.38 2.68–20.30 <0.001
Ulceration 2.13 1.54–2.94 <0.001
Head and neck site 0.80 0.53–1.22 0.31
of literature there are expected controversies. The limitations
of retrospective analyses generate an inherent ambiguity in
the signiﬁcance of the data. Our study addresses one of those
such growing paradoxes in the SLN literature in melanoma.
Increasing age has been associated with a lower frequency of
SLN positives despite both increasing age and SLN positivity
being poor prognostic features [5, 7–9].
Increased age is associated with poor prognosis in
melanoma[2,3,10,11].Multiplereportshavesuggestedthat
this ﬁnding is both an independent association and secon-
darily related to correlations with other well-known poor
prognostic features. Chao et al. in the Sunbelt Melanoma
Group, looking at 3076 patients, showed that age was asso-
ciated with increased Breslow depth, the incidence of ulcera-
tion and regression, and the proportion of male patients [5].
Our data support their ﬁndings, (however we did not assess
regression in our analysis). Further, they uniquely concluded
that increasing age was independently associated with more
SLNnegativesonmultivariableanalysis.Thisstudywaspivo-
tal in that it was the ﬁrst to suggest that there may be age-re-
lated diﬀerences in recurrence based on the paradox that in-
creasing age is associated with more distant recurrences des-
pite having more SLN-negative biopsies. However, their fol-
lowup was only 19 months, and they found no diﬀerence in
regional versus distant recurrences. Sassen et al. at the Mela-
noma Institute Australia with a sample size of 2303 reached a
similar conclusion and that there was no diﬀerence in distant
versus regional recurrence based on age [11].
Younger age is independently associated with more posi-
tive-SLNbiopsies[5,12,13].Thisphenomenonhasledsome
groupstosuggestthatyoungerpatientsbegivenalowerthre-
shold for SLN biopsy than their older counterparts [6].
Potentialbiologicexplanationsforthisepidemiologicﬁnding
are that younger patients have “more competent immune
systems,” or that lymphatic function may be impaired in
older patients [5, 14, 15]. Unfortunately, the intricacies of
these hypotheses have not been mechanistically or empiri-
cally described. The Melanoma Institute Australia attemptedInternational Journal of Surgical Oncology 5
to address a mechanism for this ﬁnding. They hypothesized
that younger patients, despite their high frequency of SLN
positives, harbor fewer metastatic nodes because of a more
intact immune system. But on examination of all positive
nodes (SLN and non-SLN), the mean total number of
positive nodes removed did not vary according to age [11].
Examining the same issue, Conway et al. at the John Wayne
CancerInstituteweresuccessfulatdemonstratingage-related
lymphaticdysfunctionspeciﬁcallyformelanomapatients.By
examining mean radioactivity counts in axillary, inguinal,
andcervicallymphnodebasins,therewasastatisticallysigni-
ﬁcant trend with lower counts in all basins in older pa-
tients. They proposed that increasing age can modify meta-
static patterns [16]. To date, this is the only study to address
anatomic and protective immunity diﬀerences as they relate
to age and melanoma. Potentially the mitotic index, a patho-
logic feature with established prognostic value, may act as
a surrogate marker for biologic activity and recurrence. We
have recently begun to analyze this factor in our database,
and cannot comment on its utility in our hypothesis.
Our study, with an extended mean followup (80.3
months) is the ﬁrst to suggest that increased age is associated
with increased distant metastasis, and this may explain the
worse prognosis for these older patients. But we also con-
clude, like the Sunbelt Group and the Michigan cohort, that
younger patients are independently associated with fewer
positive SLNs and better survival. This conclusion in our
dataset was upheld on multivariable analysis, albeit not as
strong as other prognostic features (Table 5). The only fund-
amental diﬀerences in our study from the Sunbelt Trial and
the Australia group as mentioned previously were that our
group’s SLN biopsies were performed by only 3 surgeons
(KAD, GWC, DRM) between 1998 and 2009, as opposed to
multiple centers with many surgeons. Further, we had a larg-
er proportion of head and neck cases 15.6%, a feature show-
ing to have increasing prognostic value and unique SLN
drainage implications [17].
While studies like ours and others continue to pose new
questions and conundrums, the future of retrospective pro-
babilistic models which truly elucidate the beneﬁts and pro-
gnostic value of SLN lies in elegant predictive nomograms
that take into account more speciﬁc features of melanoma
and age-related variations in primary tumor characteristics
and host immunity. The features within these prediction
models will incorporate a mechanistic foundation of SLN
metastasis which we currently have not uncovered.
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